Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients
- 1 May 2016
- journal article
- Published by SAGE Publications in Human Antibodies
- Vol. 24 (3-4) , 65-70
Abstract
OBJECTIVES: Multiple sclerosis (MS) is an autoimmune disease involving the central nervous system (CNS) with unknown immunopathogenic mechanisms. Matrix metalloproteinase-9 (MMP-9) facilitates T-cell migration into the CNS while the tissue inhibitor matrix metalloproteinase-1 (TIMP-1) inhibits MMP-9 actions. The aim of this study was to evaluate the expression of TIMP-1 RNA and MMP-9/TIMP-1 RNA ratio in blood cells of Iranian patients with relapsing-remitting multiple sclerosis (RRMS) treated with IFNb. MATERIAL AND METHODS: The study compared the expression level of TIMP-1 gene in RRMS samples with normal individuals in Iran and the results were compared using a ratio of MMP-9 to TIMP-1. All patients were HLA-DRB1*15 negative and were responders to interferon-beta with a normal vitamin D level. RESULTS: The RRMS patients manifested a lower expression level of TIMP-1 RNA than their normal counterparts although the result was not significant (P= 0.06). Also, the ratio of MMP-9 to TIMP-1 RNA increased significantly (P= 0.009). There was no linear correlation between TIMP-1 expression level and risk of Expanded Disability Status Scale of Kurtzke(EDSS); nor was there any significant correlation between expression status of TIMP-1 and duration of the disease. Although there was no significant decrease in TIMP-1 expression level, the MMP-9/TIMP-1 RNA ratio in RRMS was significantly higher than normal subjects. CONCLUSION: Further studies are recommended to compare MMP-9/TIMP-1 RNA ratio in patients before and after taking IFN-beta in order to find out if MMP-9/TIMP-1 RNA ratio can function as a proper marker of the bio efficacy of IFN-beta treatment of MS.Keywords
This publication has 23 references indexed in Scilit:
- The effect of Base Transceiver Station waves on some immunological and hematological factors in exposed personsHuman Antibodies, 2017
- The association of −330 interleukin‐2 gene polymorphism and HLA‐DR15 allele in Iranian patients with multiple sclerosisInternational Journal of Immunogenetics, 2014
- Effect of interferon β-1a on serum matrix metalloproteinase—9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patientsJournal of Neurology, 2004
- Interferon-?-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosisJournal of Neurology, 2003
- IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMSNeurology, 2003
- Metalloproteinases in biology and pathology of the nervous systemNature Reviews Neuroscience, 2001
- Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9Annals of Neurology, 1996
- Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosisAnnals of Neurology, 1996
- Interferon β decreases T cell activation and interferon γ production in multiple sclerosisJournal of Neuroimmunology, 1993
- Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functionsPharmacology & Therapeutics, 1993